Results 111 to 120 of about 47,221 (287)

Exploiting ALK inhibition in anaplastic large cell lymphoma: Biological rationale and therapeutic integration

British Journal of Haematology, EarlyView.
Summary Mature T‐cell lymphomas comprise a heterogeneous group of aggressive non‐Hodgkin lymphomas with limited therapeutic options in the relapsed or refractory setting. Among them, anaplastic lymphoma kinase (ALK)‐positive anaplastic large cell lymphoma (ALCL) represents a biologically distinct subtype driven by constitutive activation of ALK fusion ...
Santino Caserta, Enrica Antonia Martino, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Marco Fiorillo, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +13 more
wiley   +1 more source

Improved survival with fludarabine‐based therapies in mixed phenotype acute leukaemia: A population‐based study using the WHO 2022 classification

British Journal of Haematology, EarlyView.
Summary Mixed phenotype acute leukaemia (MPAL) is a rare subtype of acute leukaemia possessing significant therapeutic challenges, as no standardized, evidence‐based treatment regimen has been defined. In this nationwide study, we aimed to assess the effect of an acute lymphoid leukaemia (ALL)‐like regimen; an acute myeloid leukaemia (AML)‐like regimen;
Lisa‐Maj Christensen, Mikkel Runason Simonsen, Jonas Faartoft Jensen, Daniel Tuyet Kristensen, Karen Dybkær, Kirsten Grønbæk, Tarec Christoffer El‐Galaly, Marianne Schmidt Ettrup, Hans Beier Ommen, Anne Louise Tølbøll Sørensen, Dennis Lund Hansen, Marianne Tang Severinsen   +11 more
wiley   +1 more source

Research Progress on the Mechanism, Monitoring, and Prevention of Cardiac Injury Caused by Antineoplastic Drugs—Anthracyclines

Biology
Anthracyclines represent a highly efficacious class of chemotherapeutic agents employed extensively in antitumor therapy. They are universally recognized for their potency in treating diverse malignancies, encompassing breast cancer, gastrointestinal ...
Yuanyuan Chen, Wenwen Yang, Xiaoshan Cui, Huiyu Zhang, Liang Li, Jianhua Fu, Hao Guo   +6 more
doaj   +1 more source

Beneficial Effects of Oral Carbon Monoxide on Doxorubicin‐Induced Cardiotoxicity

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Doxorubicin and other anthracyclines are crucial cancer treatment drugs. However, they are associated with significant cardiotoxicity, severely affecting patient care and limiting dosage and usage.
Rodrigo W. Alves de Souza, Vanessa Voltarelli, David Gallo, Sidharth Shankar, Michael S. Tift, Mark Young, Edward Gomperts, Andrew Gomperts, Leo E. Otterbein   +8 more
doaj   +1 more source

Second‐generation prokineticin PKR1 receptor agonists: Advancing cardioprotection against chemotherapy‐induced toxicity

British Journal of Pharmacology, EarlyView.
IS39, a novel non‐peptide PKR1 agonist, confers cardioprotection against doxorubicin‐induced toxicity. IS39 activates PKR1‐mediated pro‐survival signalling in cardiomyocytes, reducing reactive oxygen species (ROS), DNA damage and fibrosis markers. In vivo, IS39 preserves cardiac geometry and function in mice exposed to chronic doxorubicin challenge ...
Anais Audebrand, Simone Brogi, Mustafa Tezeren, Andrea Tafi, Omer H. Ocak, Hasan Koyuncu, Igor Tetko, Laurent Désaubry, Canan G. Nebigil   +8 more
wiley   +1 more source

Circulating Musclin is associated with skeletal muscle function and subclinical cardiac dysfunction in patients with cancer

British Journal of Pharmacology, EarlyView.
Background and Purpose Musclin (osteocrin) is a skeletal muscle‐derived peptide that has been implicated in cardioprotective signalling pathways. Its relevance in cancer patients, who frequently experience muscle wasting and cardiotoxicity, remains unclear. This study aimed to determine whether circulating Musclin levels reflect functional capacity and
Jannek Brauer, Daniel Finke, Sebastian Romann, Norbert Frey, Joerg Heineke, Lorenz H. Lehmann   +5 more
wiley   +1 more source

Cardiac surveillance in immune checkpoint inhibitor therapy: Insights from the Essen Cardio‐oncology Registry

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, offering improvements in survival across various malignancies. However, their toxicities pose a major challenge for cardio‐oncology units. Despite their growing importance, data on effectiveness of such specialized units in mitigating ICI‐associated ...
Elias Haj‐Yehia, Lisa Zimmer, Lena Lampe, Dimitra Vlachopoulou, Matthias Totzeck, Tienush Rassaf, Raluca I. Mincu   +6 more
wiley   +1 more source

Cardiotoxicity of BRAF/MEK inhibitors

British Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe, Valerie Lohner, Kevin Terre, Thomas Riffelmacher, Roman Pfister   +4 more
wiley   +1 more source

A comprehensive review of cancer‐induced cardiac wasting

British Journal of Pharmacology, EarlyView.
Cancer is frequently accompanied by cachexia, a systemic syndrome characterized by progressive loss of skeletal muscle mass, with or without loss of fat mass. Increasing evidence indicates that cancer can also induce cardiac muscle wasting, which is associated with structural cardiac remodelling, impaired contractile function and the development of ...
Alessia Lena, Muhammad Shahzeb Khan, Ulrich Keller, Lars Bullinger, Dominik P. Modest, Markus S. Anker   +5 more
wiley   +1 more source

PEGylated Chitosan Nanoparticles: Engineering Multifunctional Platforms for Targeted Cervical and Lung Cancer Treatment

Cancer Science, EarlyView.
Graphical representation of formation of self‐assembled PEGylated Chitosan Nanoparticles and their mechanism in tumor localization. ABSTRACT Polymer‐based nanocarriers have emerged as transformative platforms in cancer nanomedicine, enabling controlled and site‐specific delivery of therapeutic agents.
Prashant Kesharwani, Nazim Nasir, Shadma Wahab, Garima Gupta, Khang Wen Goh, Amirhossein Sahebkar   +5 more
wiley   +1 more source